Asia-Pacific Whole Exome Sequencing Market, By Component (Second-Generation Sequencing and Third-Generation Sequencing), Product and Service (Systems, Kits, and Services), Application (Drug Discovery and Development, Agriculture & Animal Research, Diagnostics, Personalized Medicine, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals and Clinics, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others), Industry Trends and Forecast to 2029.
Market Analysis and Insights
Asia-Pacific whole exome sequencing market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 18.9% in the forecast period of 2022 to 2029. The increase in healthcare expenditure and funding are the major drivers which propelled the demand of the market in the forecast period.
However, side effects associated with the treatments of whole exome sequencing may hamper the future growth of whole exome sequencing market. Adoption of strategic alliances like partnerships and acquisitions by key market players act as opportunity for the growth of whole exome sequencing market.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD
|
|
Segments Covered
|
By Component (Second-Generation Sequencing and Third-Generation Sequencing), Product and Service (Systems, Kits, and Services), Application (Drug Discovery and Development, Agriculture & Animal Research, Diagnostics, Personalized Medicine, and Others), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Hospitals and Clinics, Clinical Laboratories, and Others), Distribution Channel (Direct Trade, Retail Sales, and Others)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific
|
|
Market Players Covered
|
Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.
|
Whole Exome Sequencing Market Definition
Whole exome is a genomic technique for sequencing all of the protein-coding region of genes in a genome. Whole exome sequencing is available to patients who are searching for a unifying diagnosis for multiple medical conditions. A laboratory process that is used to determine the nucleotide sequence primarily of the exonic (or protein-coding) regions of an individual’s genome and related sequences, representing approximately 1% of the complete DNA sequence, also called WES. Whole-exome sequencing is a widely used whole exome sequencing method that involves sequencing the protein-coding regions of the genome. The human exome represents less than 2% of the genome, but contains ~85% of known disease-related variants, making this method a cost-effective alternative to whole-genome sequencing.
Exome sequencing using exome enrichment can efficiently detect coding variants across a wide range of applications, including population genetics, genetic disease and cancer studies. The growth of the global whole exome sequencing market is attributed to the reduction in time and cost for sequencing. With the development of new technologies and cancer cure treatment, the whole exome sequencing market in clinical oncology has huge potential in the coming years.
Asia-Pacific Whole Exome Sequencing Market Dynamics
Drivers
- Increase in the adoption of next generation sequencing (NGS)
As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.
NGS offers advantages in accuracy, sensitivity, and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.
- Growing usage of targeted sequencing methods
As genomics-focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at molecular underpinnings of individual tumours and specific receptors.
NGS offers advantages in accuracy, sensitivity and speed compared to traditional methods that have the potential to make a significant impact on the field of oncology. Because NGS can assess multiple genes in a single assay, the need to order multiple tests to identify the causative mutation is eliminated.
Restraint
-
Less comprehensive coverage of exons
All the exons are not comprehensively captured. The exon of importance may not be included in the current standard annotations of the human genome; and it is merely arduous to cover 100% of the exome with the current WES technology. Consequently, disease-causing variants in these “missed” exons go undetected.
WES has low sensitivity for structural variations, hence detection is limited. Nonetheless some CNVs, including indels and duplications, can be detected by WES, the technical limitation implies that others are likely missed
Opportunity
-
Strategic Initiatives by the key market player
The demand for whole exome sequencing is increasing in the market owing to the increased incidence of genetic disease along with the increased geriatric population across the region. Thus, the top market players have implemented the strategy of collaboration with other market players aimed at improving business operations and profitability.
Challenge
- Ethical and legal issues related to whole exome sequencing
Rapid advances in high throughput genomic technologies and next generation sequencing are making medical genomic research more readily accessible and affordable, including the sequencing of patients and control whole genomes and exomes in order to elucidate genetic factors underlying disease. Progress of high throughput genomic technologies and next generation sequencing (NGS) methods in recent years has changed the scope of human genomic studies. These advances have made it feasible to routinely perform whole exome sequencing studies.
Due to the large-scale, collaborative nature of studies, ethical and legal issues are of increasing concern and have important implications in Africa. African populations are of unique interest because, despite having the highest levels of genetic diversity, living in a vast array of environmental and cultural settings, as well as suffering from a high burden of disease that could be studied using genomics approaches, they are facing legal issues in WES.
Post COVID-19 Impact on Whole Exome Sequencing Market
COVID-19 has resulted in a substantial upsurge in demand for medical supplies from both healthcare professionals and the general public for precautionary measures. Manufacturers of these items have an opportunity to take advantage of the increased demand for medical supplies by ensuring a steady supply of personal protective equipment on the market. COVID-19 is anticipated to have a big impact on the whole exome sequencing market.
Recent Development
- In May, 2022, Thermo Fisher Scientific, the world leader in serving science, and Qatar Genome Program (QGP), a member of Qatar Foundation (QF), have partnered with the goal of accelerating genomic research and clinical applications of predictive genomics in Qatar as a step toward expanding the benefits of precision medicine across Arab populations globally. This has helped the company to expand its presence.
- In March, 2022, several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic testing in cardiology. CGTA seeks to educate healthcare providers and other stakeholders about the value of such testing to assure adherence to existing guidelines from professional medical societies, to inform medical management and cascade testing, and to improve clinical outcomes. This has helped company to adhere to guidelines.
Asia-Pacific Whole Exome Sequencing Market Segmentation
Asia-Pacific whole exome sequencing market is segmented on the basis of component, product and service, application, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Component
- Second-Generation Sequencing
- Third-Generation Sequencing
On the basis of component, the Asia-Pacific whole exome sequencing market is segmented into second-generation sequencing and third-generation sequencing.
Product and Services
- Systems
- Kits
- Services
On the basis of product and service, the Asia-Pacific whole exome sequencing market is segmented into systems, kits and services.
Application
- Diagnostics
- Drug Discovery and Development
- Personalized Medicine
- Agriculture & Animal Research
- Others
On the basis of application, the Asia-Pacific whole exome sequencing market is segmented into drug discovery and development, agriculture & animal research, diagnostics, personalized medicine and others.
End User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Clinical Laboratories
- Others
On the basis of end user, the Asia-Pacific whole exome sequencing market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, hospitals & clinics, clinical laboratories and others.
Distribution Channel
- Direct Trade
- Retail sales
- Others
On the basis of distribution channel, the Asia-Pacific whole exome sequencing market is segmented into direct trade, retail sales and others.
Whole Exome Sequencing Market Country Level Analysis
The whole exome sequencing market is analyzed and market size information is provided by component, product and service, application, end user and distribution channel.
The countries covered in the whole exome sequencing market report are the Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific.
China most dominating due to the presence of key market players along the largest consumer market. China is expected to grow due to the rise in healthcare technological advancement.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Whole exome sequencing market also provides you with detailed market analysis for every country growth in the healthcare industry. Moreover, it provides detailed information regarding healthcare services and treatments, impact of regulatory scenarios, and trending parameters regarding whole exome sequencing market.
Competitive Landscape and Whole Exome Sequencing Market Share Analysis
Whole exome sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Whole exome sequencing market.
The major companies which are dealing in the whole exome sequencing market are Thermo Fisher Scientific Inc., QIAGEN, Illumina, Inc., Beckman Coulter, Inc., Eurofins Scientific, BIONEER CORPORATION, ExoDx (a part of Bio-Techne), FOUNDATION MEDICINE, INC. (A subsidiary of F. Hoffmann-La Roche Ltd), GeneFirst Limited, CeGaT GmbH, Meridian, Merck KGaA, SOPHiA GENETICS, Azenta U.S. Inc., CD Genomics, Twist Bioscience, PerkinElmer Genomics (A Subsidiary of PerkinElmer Inc.), GeneDx, LLC, Psomagen, Integrated DNA Technologies, Inc., among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional and Vendor Share Analysis. Please request analyst call in case of further inquiry.
SKU-